Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00926783 · ClinicalTrials.gov registry record · Phase 4
Selective Complex Fractionated Atrial Electrograms (CFAE) Targeting for Atrial Fibrillation
A Phase 4 study of Atrial Fibrillation, sponsored by Biosense Webster.
- Completed
- Registry status
- Phase 4
- Development phase
- 86
- Enrollment target
- 7
- Study locations
NCT00926783 is a Phase 4 study of Atrial Fibrillation that has completed, run by Biosense Webster. The registered enrollment target is 86 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (97% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT00926783, a Phase 4 study of Atrial Fibrillation, has completed, sponsored by Biosense Webster.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 86 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study will be a multicenter, open, prospective, randomized trial. Patients with either paroxysmal or persistent atrial fibrillation will be considered for the study. (For US, only paroxysmal atrial fibrillation will be considered.) Eligible subjects will be randomized into one of two arms in the study: (1) targeted CFAE ablation or (2) generalized CFAE ablation. Both techniques will then be followed by PVAI (pulmonary vein antral isolation) as part of a hybrid ablation strategy. The nature of the ablation procedures does not allow physicians to be blinded to the randomization.
Conditions Studied
Interventions
- PROCEDURE CFAE ablation
Study Locations (7)
Ontario
- Hamilton Health Sciences Centre - Hamilton
- Southlake Regional Health Center - Newmarket
Quebec
- Montreal Heart Institute - Montreal
- Hopital Laval - Institut universitaire de cardiologie et de pneumonologie - Québec
Illinois
- Loyola University Medical Center - Maywood
Maryland
- Johns Hopkins University - Baltimore
South Australia
- Royal Adelaide Hospital - Adelaide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2009-08 |
| Est. Completion | 2013-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00926783
The ClinicalTrials.gov registry entry for NCT00926783 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (97% lower). The listed sponsor is Biosense Webster, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which CFAE ablation is the first listed.
NCT00926783 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Ontario, Quebec, Illinois.
Frequently Asked Questions
What is clinical trial NCT00926783 about?
NCT00926783 is a clinical study titled "Selective Complex Fractionated Atrial Electrograms (CFAE) Targeting for Atrial Fibrillation". This study will be a multicenter, open, prospective, randomized trial. Patients with either paroxysmal or persistent atrial fibrillation will be considered for the study. (For US, only paroxysmal atrial fibrillation will be considered.) Eligible subjects will be randomized into one of two arms in th...
What is the current status of trial NCT00926783?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 86 participants. The study started on 2009-08. Estimated completion is 2013-09.
What conditions does trial NCT00926783 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT00926783?
The interventions under investigation include: CFAE ablation (PROCEDURE).
Who is sponsoring clinical trial NCT00926783?
This trial is sponsored by Biosense Webster, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00926783 being conducted?
This trial has 7 study locations across Illinois, Maryland, South Australia, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
RECRUITING · Phase 4
-
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
RECRUITING · Phase 4
-
Ondansetron for the Management of Atrial Fibrillation
RECRUITING · Phase 4
-
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
ACTIVE NOT RECRUITING · Phase 4
-
Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.